News
The OIS Index of ophthalmic stocks gave back some of its recent gains in September, declining by 4.1% against an overall flat market backdrop. The…
Read More
At OIS@ASRS 2016, Forrest Fleming, then CEO of TrueVision Systems, announced a new partnership with Alcon. He also introduced the result of that pairing: the…
Read More
Netherlands-based Preceyes BV seems to have taken the lead in the race to develop a robotic platform for retinal surgery as it prepares to demonstrate…
Read More
With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class…
Read More
The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index…
Read More
In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to…
Read More
Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’…
Read More
Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies…
Read More
The OIS Index of ophthalmic stocks declined by 1.1% in July, against a strong overall market backdrop. During the month, the overall US stock market…
Read More
When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an…
Read More
Two forces are emerging in healthcare that could determine how quickly personalized medicine takes over: an outcomes-based system that pays drug makers only when their…
Read More
Last week, one day before the American Society of Retina Specialists and OIS Retina convened in Vancouver, Allergan and its collaborative partner Molecular Partners touted…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")